The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Second pass at: Reimbursement variation across member states

This is a generated summary. It shows the 5 most-liked posts from a topic of 29, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
K
KTurkingtonTL3Regular11 Sep 2024#8

On post #4 — agreed on the reasoning, with one qualification.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

21 likes 23mo
BA
b.aaltoTL2 Moderator20 Sep 2024#11
KTurkington, post #8: On post #4 — agreed on the reasoning, with one qualification. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive. Go to post

EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member state.

22 likes in reply to #8 22mo
SC
s.cabreraTL2 Moderator10 Oct 2024#18

Picking up post #15: that is the part I would want checked first.

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

31 likes 22mo
CS
c.serranoTL2 Moderator21 Oct 2024#22

Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available.

29 likes 21mo
K
KAnderssonTL3Regular7 Nov 2024#29

post #28 answers the question as asked. The question underneath it is different.

Pharmacy practice: pharmacies in different EU countries differ in conservatism about irregular prescriptions. Some will decline a prescription they consider irregular; others will not. Local pharmacy culture matters.

28 likes 21mo

Read the full topic (29 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
EMA product information as a primary source
Posting this under the heading it deserves: EMA product information as a primary source Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this category…
YISVCDAMB+70 74 7k 8mo
German, French and Dutch differences, compared
German, French and Dutch differences, compared — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what determines the…
AKMMR 2 12k 10h
Cross-border purchase rules within the EU
On the subject in the title: Cross-border purchase rules within the EU Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what determines the answer.…
HMEFVKGZA+45 49 15k 8mo
EMA product information as a primary source — does this still hold?
The question in the title: EMA product information as a primary source — does this still hold? I will give what I have already checked below so nobody repeats it. Documenting an access outcome, dated, because…
CCSGRWIAII+127 150 41k 20mo
Revisiting: German, French and Dutch differences, compared
Posting this under the heading it deserves: Revisiting: German, French and Dutch differences, compared Everything below is what sits behind that. A coverage question with the paperwork detail included, since…
ITKSTHEDS+90 99 32k 9mo

Related topics — sharing the tags personal import, formulary, cost per milligram

TopicParticipantsRepliesViewsActivity
Prescription requirements and telehealth models — a second dataset
On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. A logistics question, since the answers here are usually better than…
MOLAPFPHB+87 94 1.1k 21d
Tracking a shortage from primary sources rather than rumour — the long version
On the subject in the title: Tracking a shortage from primary sources rather than rumour — the long version Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in…
SDLSNM 2 60 1d
Price changes over 2025 and 2026, tabulated and dated — does this still hold?
Price changes over 2025 and 2026, tabulated and dated — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Documenting an access outcome, dated,…
WMCCDFKSDO+147 156 18k 3mo
Reimbursement variation across member states
Reimbursement variation across member states Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what…
SFJSREBS+7 11 39k 3mo
Managing an unplanned gap in supply — what changed since
On the subject in the title: Managing an unplanned gap in supply — what changed since Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what…
FEELIGRAC+114 124 54k 8mo